Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The antibody-drug conjugate Tivdak led to remission in 24% of cervical cancer patients.
Third booster dose may improve immune response in cancer patients without sufficient protection after second dose.
Adding the CDK 4/6 inhibitor to hormone prolonged survival by a year.
Opdivo plus relatlimab delayed disease progression compared with Opdivo alone.
A large number of cancer survivors still suffer from significant health issues years after being declared disease-free.
The committee voted against third shot for all adults, however, casting doubts on Biden’s booster plan.
Exkivity is approved for adults with advanced non-small-cell lung cancer with specific EGFR mutations.
A higher dose of cisplatin and combination with other medications influence the development of hearing loss.
Many older people have biomarkers indicative of a strong response to checkpoint inhibitors.
National Cancer Institute study describes three molecular subtypes of lung cancer in people who have never smoked.
Active surveillance has increased over time, but many men transition to treatment within five years.
Community clinics in low-income communities saw a decline in breast cancer screening during the pandemic, new report finds.
People who received a higher dose had stronger and longer-lasting immune responses.
Certain types of cancer treatment can lead to inadequate immune response.
The IDH1 inhibitor is the third medication approved this year for hard-to-treat bile duct cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.